Fundamentally, acquired therapy resistance can be driven by changes to previously sensitive cancer cells or their environment (e.g., acquisition of AR amplification or activating mutations following therapies that inhibit the androgen receptor, AR) and/or by the outgrowth of cancer cells with primary resistance (i.e., clonal selection)1,2. Here, AR is linked to cancer.